2002 Pa 194

PTO/SB/30 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request

Application Number

09/830,968

## for Continued Examination (RCE) Transmittal

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ed to respond to a collection of informa	tion unless it contains a valid OMB control number.
Application Number	09/830,968
Filing Date	November 6, 2001
First Named Inventor	Carlos Miguel Carcagno
Art Unit	1636
Examiner Name	Kaushal, Sumesh
Attorney Docket Number	1909.0040002/JAG/PAJ

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

<ol> <li>Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).</li> </ol>	
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.	
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
li. Other	
b. X Enclosed	
I. $X$ Amendment/Reply iii. $X$ Information Disclosure Statement (IDS)	
ii. Affidavit(s)/ Declaration(s)  iv. X Other <u>Certified Copies of Priority Applications</u>	
2. Miscellaneous	
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a  a. period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)	
b. Other	
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.	
The Director is hereby authorized to charge the following fees, or credit any overpayments, to	
a. X Deposit Account No. 19-0036 . I have enclosed a duplicate copy of this sheet.	
i. X RCE fee required under 37 CFR 1.17(e)	
i. X RCE fee required under 37 CFR 1.17(e)  ii. Extension of time fee (37 CFR 1.136 and 1.17)	
iii. Other	
b. Check in the amount of \$enclosed	
c. X Payment by credit card (Form PTO-2038 enclosed)	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Signature Date 4/21/05 Name (Print/Type) Poter A Tackman Registration No. 45 986	
Telei A. Jackinaii	
CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.	
Signature	
Name (Print/Type) Date	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USP10 to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carcagno et al.

Appl. No.: 09/830,968

§ 371 Date: November 6, 2001

For: Method for the Massive Culture of Cells Producing Recombinant

**Human Erythropoietin** 

Confirmation No.: 7301

Art Unit: 1636

Examiner: Kaushal, Sumesh

Atty. Docket: 1909.0040002/JAG/PAJ

## Amendment and Reply Under 37 C.F.R. § 1.114

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated January 21, 2005, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims; and
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net

addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.